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Background:  Prophylactic  paracetamol  (PP)  was  previously  shown  to reduce  primary  and  booster  antibody
responses  against  the  10-valent  pneumococcal  non-typeable  Haemophilus  inﬂuenzae  protein  D  conjugate
vaccine  (PHiD-CV).  This  study  further  evaluated  the  effect  of PP  on  antibody  persistence,  immunological
memory  and  nasopharyngeal  carriage  (NPC).
Methods:  Two  hundred  and  twenty  children  previously  primed  (3 doses,  NCT00370318)  and  boosted
(NCT00496015)  with  PHiD-CV  with (PP group)  or without  (NPP  group)  prophylactic  paracetamol
administration  received  one  PHiD-CV  dose  in their  fourth  year  of  life  to  assess  the  induction  of  immuno-
logical  memory  following  previous  immunisations.  A control  group  of age-matched  unprimed  children
enrolled  in  study  NCT00496015  received  an  investigational  tetravalent  Neisseria  meningitidis  serogroups
A,  C, W-135,  Y tetanus  toxoid-conjugate  vaccine,  and thus  remained  unprimed  for  pneumococcal  vac-
cination.  Of  these,  223  unprimed  children  received  in  the  present  study  at least  one  PHiD-CV  dose  of  a
2-dose  catch-up  regimen,  which  was  relevant  as  control  for assessment  of  immunological  memory  in
PHiD-CV primed  children.
Results:  Induction  of  immunological  memory  was  shown  irrespective  of  PP  administration  at  primary  and
booster  vaccination.  Antibody  geometric  mean  concentrations  were  lower  in  the  PP group  for  serotypes
1,  4,  7F  and  9V.  Opsonophagocytic  titres  did  not  differ  signiﬁcantly  between  PP  and  NPP  groups.  Previous
use  of  PP  seemed  to  have  only  a  minor  impact  on kinetics  of  antibody  persistence.  Reduced  NPC  of vac-
cine  pneumococcal  serotypes  and  trends  towards  increased  NPC  of  non-vaccine  and non-cross-reactive
serotypes  were  seen  in primed  groups  versus  the  control  group,  with  no  obvious  differences  between  PP
and  NPP  groups.
Conclusion:  Regardless  of whether  previous  PHiD-CV  vaccination  was  given  with  or without  PP,  induction
of  immunological  memory  and  persistence  of  PHiD-CV’s  impact  on  carriage  was  seen  until  at  least  28
months  post-booster  vaccination.  Our  study  results  therefore  suggest  that  the  lower  immune  responses
after  primary  and  booster  vaccination  with  PP  are  of  transient  nature.Abbreviations: AE, adverse event; ATP, according-to-protocol; BS, blood sample; CPS
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. Introduction
Bacterial capsular polysaccharides such as those from
treptococcus pneumoniae (S. pneumoniae) fail to induce adequate
mmune responses in young infants. However, conjugation to a
arrier protein transforms T-cell independent polysaccharide anti-
ens into T-cell dependent antigens capable of inducing immune
esponses and immunological memory in neonates and infants [1].
he 10-valent pneumococcal non-typeable Haemophilus inﬂuen-
ae protein D conjugate vaccine (PHiD-CV) induced anamnestic
esponses following a booster dose in 1–2-year-old children [2–8]
nd in 3–4-year-old children [9,10].
Nasopharyngeal carriage (NPC) of S. pneumoniae is considered to
sually precede pneumococcal disease [11,12]. Pneumococcal con-
ugate vaccines (PCVs) are able to induce an immune response early
n infancy, when pneumococcal NPC is being acquired and carriage
ates are the highest. As a result, PCVs were shown to reduce NPC
f vaccine pneumococcal serotypes, but also tend to increase car-
iage of non-vaccine pneumococcal serotypes not cross-reacting
ith vaccine serotypes (replacement) [13]. Similar impacts of vac-
ination with PHiD-CV on NPC were documented previously [14].
This long-term follow-up study aimed to assess immunologi-
al memory induced by primary and booster vaccination through
valuation of early immune responses after an additional dose of
HiD-CV (primary objective), and to evaluate long-term antibody
ersistence and NPC (secondary objectives). Reactogenicity and
afety of the PHiD-CV dose were also documented.
Paracetamol (acetaminophen) administered prophylactically
PP) at the time of primary vaccination was previously shown to
ubstantially reduce antibody responses to PHiD-CV. This effect
ersisted, although less marked, following booster vaccination
15]. We  also described a reduced NPC of pneumococcal vaccine
erotypes following primary vaccination with PHiD-CV that was
ore pronounced prior to booster vaccination in children who  had
ot received PP and waned after the booster dose [14]. Therefore,
n additional aim of the study was to explore the long-term effects
f PP on the induction and persistence of immunological memory
nd on the reduction of pneumococcal NPC.
. Methods.1. Study design and participants
This phase III, open-label, controlled study (NCT00950833) was
onducted in 9 health centres in the Czech Republic between
Primary vac cination  study
Randomisation  1:1
B
PP group 
NPP grou p 
Age (months)  at
study visits
±3 ±4 ±5 ±6 12-15 13 -1
Vacc ination
PHiD-CV  + DTPa-HBV -IPV/Hib
Rotavi rus  vacc ine
PP and  NPP  grou 
Control  group : Me 
Blood sampling * * 
Nas ophar yngea l
swab
* 
NCT0 0370318 
ig. 1. Study design. *Pre-vaccination; **7–10 days after the additional PHiD-CV dose in th1 (2013) 2080– 2088 2081
August 2009 and October 2010. The study population consisted
of healthy children, aged 31–44 months, previously primed with
PHiD-CV at 3, 4 and 5 months of age and boosted at 12–15 months
of age and of a non-randomised age-matched PCV-naïve control
group enrolled at the time of booster vaccination (Fig. 1) [15].
PHiD-CV primed groups were randomised (1:1) in the primary
vaccination study (Fig. 1) into the PP group who received paracet-
amol prophylactically at the time of vaccination and every 6–8 h
within the ﬁrst 24 h after each vaccine dose, or the NPP group who
received no prophylactic antipyretics [15].
PHiD-CV primed groups received a single (ﬁfth) PHiD-CV dose at
40–48 months of age (Fig. 1). The unprimed control group received
2 PHiD-CV doses; the ﬁrst dose at 40–48 months of age and the
second dose at least 2 months (56–118 days) later. The ﬁrst PHiD-
CV dose was relevant as control for assessment of immunological
memory in PHiD-CV primed groups. The second dose completed
the 2-dose catch-up vaccination regimen for which the results will
be published separately.
The study was  undertaken according to Good Clinical Practice
guidelines and the Declaration of Helsinki. The study protocol
was  approved by ethics review committees of participating cen-
tres. Written informed consent was  obtained from the parents or
guardian.
2.2. Study vaccine
PHiD-CV (SynﬂorixTM, lot number ASPNA002B) manufactured
by GlaxoSmithKline (GSK) Vaccines, contained 1 g of each cap-
sular polysaccharide (CPS) for pneumococcal serotypes 1, 5, 6B, 7F,
9V, 14, and 23F, and 3 g for serotype 4 conjugated individually to
protein D, 3 g of serotype 18C CPS conjugated to tetanus toxoid,
and 3 g of serotype 19F CPS conjugated to diphtheria toxoid. The
vaccine was administered intramuscularly into the deltoid using a
25 mm (1 in.), 22–25 gauge needle.
2.3. Immunogenicity assessment
Blood samples for the assessment of persistence of immune
responses and immunological memory were taken prior to and
7–10 days after administration of the ﬁrst PHiD-CV dose in the
current study (Fig. 1).ooster  vaccin ation stu dy Present  follow-up study
PP grou p PP  group
NPP grou p NPP  group
Control Con trol
6 15 -18 19 -22 24 -27 31 -44 40 -48 40 -48
Visit 1 Visit 2 Visit 3
ps: PHiD-CV  + DTPa-HBV-IPV /Hib
nACWY-TT  + DTPa-HBV -IPV/Hi b
PHiD-CV
* **
*
NCT0049601 5 NC T0095 0833
e PP and NPP groups; 7–10 days after the ﬁrst dose of PHiD-CV in the control group.
(22F-ELISA) using a threshold antibody concentration of 0.2 g/ml
as described previously [16–18] was  used to measure anti-
pneumococcal serotype-speciﬁc total IgG concentrations.
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Opsonophagocytic activity (OPA) was measured by a pneumo-
occal killing assay with a cut-off opsonic titre of 8 as described
reviously [19].
Anti-protein D geometric mean antibody concentrations (GMCs)
ere determined using an in-house ELISA assay with a 100 EL.U/ml
ut-off.
Time points pertaining to the previous primary and booster vac-
ination studies are also considered in the present manuscript to
how kinetics of immune responses in the same cohort over time.
erological results of blood samples collected 12 months post-
ooster in the previous booster study were used in the present
tudy to evaluate antibody persistence.
.4. Carriage assessment
Nasopharyngeal swabs were collected at 31–44 and 40–48
onths of age (Fig. 1). Time points pertaining to the previous
ooster study are also considered in this manuscript to allow a
ong-term assessment of nasopharyngeal colonisation.
Samples were cultured for identiﬁcation of S. pneumoniae,
on-typeable H. inﬂuenzae (NTHi) and other bacteria includ-
ng Staphylococcus aureus (S. aureus) and Moraxella catarrhalis
M.  catarrhalis) using standard bacteriological methods [20].
asopharyngeal swab isolates initially identiﬁed as H. inﬂuenzae
ere further differentiated from Haemophilus haemolyticus with a
hole-cell ELISA assay [21].
.5. Safety assessment
Parents or guardians were asked to complete diary cards
o report local (pain, redness and swelling) and general symp-
oms (fever, irritability/fussiness, drowsiness and loss of appetite)
olicited on the day of vaccination and for 3 subsequent days.
nsolicited adverse events (AEs) were recorded for 31 days after
accination. Serious adverse events (SAEs) were recorded during
he entire study period.
.6. Statistical analysis
Immunogenicity analysis (including results pertaining to pre-
ious primary and booster vaccination time points) was  done
n the according-to-protocol (ATP) cohort for immunogenicity
f the present follow-up study, comprising all children with the
esults available and who  complied with study procedures and
ntervals for vaccination and blood sampling. Percentages of chil-
ren with pneumococcal antibody concentrations ≥0.20 g/ml and
hose with OPA titres ≥8 were calculated for PHiD-CV and cross-
eactive (6A and 19A) pneumococcal serotypes with exact 95%
onﬁdence intervals (CIs). Antibody GMCs and OPA geometric mean
itres (GMTs) were calculated with 95% CIs. Statistically signiﬁcant
ifferences were inferred from non-overlapping 95% CI boundaries.
o adjustment was done for multiple comparisons and statisti-
ally signiﬁcant differences should therefore be considered only
ndicative of possible differences between groups or time points.
A statistically signiﬁcant difference between immune responses
n primed versus unprimed subjects can be considered to be indica-
ive of prior immunological priming. The primary objective was
herefore deﬁned as demonstration of induction of immunologi-
al memory, and would be reached if for each of the 10 vaccine
neumococcal serotypes the lower limit of the 95% CI around the
ost-vaccination GMC  ratios (pooled PHiD-CV primed groups over
nprimed group) was higher than 1. A global power of 93.2% was
alculated based on an expected sample size of 339 subjects (189
n the pooled PHiD-CV primed groups and 184 in the unprimed
roup).1 (2013) 2080– 2088
NPC was  analysed based on the ATP cohort for carriage com-
prising all participants with results available and who  complied
with the study procedures and intervals for vaccination and swab
sampling. The percentage of children with conﬁrmed colonisation
was  calculated per group, bacteria and serotype, at each swab
time point. Vaccine efﬁcacy (VE) was  estimated as [(1 − relative
risk) × 100] and was calculated with 95% CI (conditional exact
method) at each time point. Carriage results related to time points
of the previous booster study were re-analysed and presented here
based on the ATP cohort for carriage of the current study.
No adjustment for multiplicity was  done. Statistical signiﬁcance
on VE was concluded if the 95% CI around VE was not containing
zero.
Analysis of safety and reactogenicity was  performed on the total
vaccinated cohort.
The sample size of the primed PP and NPP groups was contingent
on the number of children who  received a full vaccination course
(i.e. a 3-dose primary vaccination and a booster vaccination in the
previous primary and booster studies) with PHiD-CV. The sample
size of the unprimed group depended on the number of children
who  received one dose of MenACWY-TT in the previous booster
study.
Statistical analyses were performed using SDD (Statistical Anal-
ysis Software [SAS] Drug and Development) web portal and SAS
version 9.2.
3. Results
3.1. Study population
Four hundred and sixty-one children were enrolled, of which
443 completed the study and were part of the total vaccinated
cohort. Of the children who  participated in the previous booster
study and were planned to be enrolled in the present follow-up
study, 225 did not participate. Reasons for non-participation and
exclusion from ATP cohorts are documented in Fig. 2. Children
for whom PP administration in the primary vaccination study was
discontinued in the booster vaccination study as the result of a pro-
tocol amendment as well as subjects primed and boosted without
PP after the implementation of the protocol amendment were not
invited for this follow-up study.
Demographic proﬁles were comparable between groups and did
not differ between the ATP cohort for immunogenicity (Table 1) and
the ATP cohort for carriage.
3.2. Immunogenicity
As expected, a decline in antibody GMCs and OPA GMTs
was  observed in the PHiD-CV primed groups between 1 and 12
months following PHiD-CV booster vaccination, with a further
less pronounced decline over the subsequent 18 months, with the
exception of antibody GMCs for serotypes 6B, 19F and 23F and OPA
GMTs for serotypes 6B and 19F (Supplementary Fig. 1). Prior to
revaccination for each vaccine serotype the percentage of subjects
with immune response ≥ELISA threshold was at least 63.9% except
for serotypes 1 and 4, while for OPA threshold it was at least 64.5%
except for serotypes 1, 4, 5 and 18C (Tables 2 and 3). Antibody GMCs
were lower in the PP group than in the NPP group, with borderline
statistical signiﬁcant differences for serotypes 1, 4 and 5 (Table 2).
Similarly higher OPA GMTs values were observed in the NPP group
for serotypes 4, 5 and 19F (non-overlap of 95% CIs) (Table 3).Seven to 10 days following vaccination, robust increases in anti-
body GMCs and OPA GMTs were observed in the PHiD-CV primed
groups, regardless of prior administration of PP (Tables 2 and 3,
Supplementary Fig. 1). Depending on the serotype, antibody GMCs
R. Prymula et al. / Vaccine 31 (2013) 2080– 2088 2083
Total vaccinated  coho rt of
previous  boo ste r stud ya
PP
N = 178
NPP
N = 172
Con tro l
N = 33 6
Reasons  for not pa rtici pating  in  the  follo w-up
study:
- not eligib le 2 3 28
- lost to follo w-up 18 9 23
- not willing  to  partic ipate  due  to other reason  tha n
 AE/SAE
42 46 54
Total effective  coh ort of
follow-up stud yb
PP
N = 116
NPP
N = 114
Con tro l
N = 23 1
Withdrawal  before  Visit  2c:
- con sent with drawal N=4 N=6 N=5
- withd rawal  after a fi rst epi sode  of ep ile psy N=1
- migr ated/ moved  from stu dy are a N=1
- lost to follo w-up N=1
Total vaccin ated  coho rt PPN = 112
NPP
N = 108
Con tro l
N = 22 3
Exclus ions  from the  ATP coho rt fo r
immunogeni city:
- administration  of vacci ne(s) forb idden  in the  proto col N=2
- pro tocol  vio lation  (in clusion /exc lus ion  crite ria ) N=2
- non-compli ance with vacc ination  schedul e N=6
- non-compli ance with blood  sampling  schedu le N=1 N=2
- ess ential  sero logical  da ta missin g N=1
Exclus ions  from the  ATP coho rt fo r carr iage:
- administration  of vacci ne(s) forb idden  in the  proto col N=2
- pro tocol  vio lation  (in clusion /exc lus ion  crite ria ) N=2
-non-compl iance with  vacc ination  schedu le N=6
-non-compl iance with  na soph aryngeal  swab  vis its N=2 N=2 N=3
ATP co hort for
immun ogeni cit y
PP
N = 11 2
NPP
N = 10 7
Con tro l
N = 21 0
ATP co hort for carriage PPN = 11 0
NPP
N = 10 6
Con tro l
N = 21 0
Fig. 2. Trial proﬁle. aChildren for whom PP administration in the primary vaccination study was  discontinued in the booster vaccination study as the result of a protocol
a tation
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Nmendment as well as subjects primed and boosted without PP after the implemen
dditional subjects were enrolled by mistake but were not considered for any analy
ose  of PHiD-CV for unprimed children.
ncreased 9.8–72.1-fold in the PP group and 8.2–59.9-fold in the
PP group from pre- to post-vaccination time points (Table 2). OPA
MTs increased 16.7–2029.6-fold in the PP group and 19.4–1097.5-
old in the NPP group (Table 3). The primary objective of the study
demonstration of induction of immunological memory) was met
ince the lower limits of the 95% CIs around the antibody GMC  ratios
pooled PHiD-CV primed groups over unprimed group) were higher
able 1
ummary of demographic characteristics – ATP cohort for immunogenicity.
PP (N = 112) 
Mean age ± SD (months) at visit 1 39.2 ± 1.5 
Mean  age ± SD (months) at vaccination 1 43.8 ± 1.5 
Gender [n, %]
Female 60 (53.6) 
Male  52 (46.4) 
Race  [n, %]
White – Caucasian/European heritage 111 (99.1) 
White  – Arabic/north African heritage 0 (0.0) 
White  – Caucasian + African heritage 1 (0.9) 
 = total number of children, n/% = number/percentage of children in a given category, SD of the protocol amendment were not invited for the present follow-up study. bFive
dministration of the PHiD-CV dose for primed children; administration of the ﬁrst
than 1 for all 10 vaccine pneumococcal serotypes (Supplementary
Table 1).
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.vaccine.2013.01.044.Seven to 10 days following vaccination in the PHiD-CV primed
groups, antibody GMCs were in the same range in the PP and NPP
groups for serotypes 5, 6B, 14, 18C, 19F and 23F, but signiﬁcantly
NPP (N = 107) Control (N = 210)
39.1 ± 1.5 37.8 ± 3.3
44.0 ± 1.6 42.9 ± 2.9
48 (44.9) 90 (42.9)
59 (55.1) 120 (57.1)
107 (100) 202 (96.2)
0 (0.0) 8 (3.8)
0 (0.0) 0 (0.0)
 = standard deviation.
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Table  2
Anti-pneumococcal antibody responses, prior to and 7–10 days after PHiD-CV vaccination (PP and NPP groups) or ﬁrst dose of PHiD-CV (control group) – ATP cohort for
immunogenicity.
Timing PP group (N = 110) NPP group (N = 106) Control group (N = 209)
% ≥0.2 g/ml (95% CI) GMC  (95% CI) % ≥0.2 g/ml (95% CI) GMC (95% CI) % ≥0.2 g/ml (95% CI) GMC  (95% CI)
Vaccine serotypes
Serotype 1 PRE 42.7 (33.3–52.5) 0.21 (0.17–0.27) 61.0 (50.9–70.3) 0.36 (0.27–0.48) 17.3 (12.4–23.1) 0.09 (0.08–0.11)
POST 99.1 (95.0–100) 5.86a (4.81–7.13) 100 (96.6–100) 10.01a (8.07–12.42) 98.0 (95.1–99.5) 1.24 (1.07–1.42)
Serotype 4 PRE 32.7 (24.1–42.3) 0.15 (0.13–0.18) 50.5 (40.5–60.5) 0.26 (0.20–0.34) 13.1 (8.8–18.5) 0.05 (0.04–0.06)
POST 99.1 (95.0–100) 10.82a (8.92–13.13) 100 (96.6–100) 15.57a (13.14–18.46) 99.5 (97.3–100) 4.52 (3.96–5.17)
Serotype 5 PRE 63.9 (54.1–72.9) 0.34 (0.28–0.41) 81.7 (72.9–88.6) 0.49 (0.41–0.59) 23.6 (18.0–29.9) 0.10 (0.09–0.11)
POST 100 (96.7–100) 8.16 (6.69–9.94) 100 (96.6–100) 11.74 (9.50–14.50) 87.6 (82.3–91.8) 0.72 (0.63–0.84)
Serotype 6B PRE 64.8 (55.0–73.8) 0.63 (0.43–0.93) 75.0 (65.6–83.0) 1.02 (0.69–1.50) 26.7 (20.8–33.4) 0.10 (0.08–0.12)
POST 99.1 (95.0–100) 7.04 (5.80–8.54) 100 (96.6–100) 8.38 (6.92–10.14) 54.7 (47.6–61.7) 0.27 (0.22–0.33)
Serotype 7F PRE 74.5 (65.4–82.4) 0.42 (0.34–0.52) 83.8 (75.3–90.3) 0.55 (0.44–0.68) 15.8 (11.1–21.5) 0.06 (0.05–0.07)
POST 99.1 (95.0–100) 5.25a (4.34–6.35) 100 (96.6–100) 8.13a (6.74–9.79) 96.6 (93.1–98.6) 1.37 (1.19–1.58)
Serotype 9V PRE 67.6 (57.9–76.3) 0.40 (0.31–0.53) 75.7 (66.3–83.6) 0.62 (0.46–0.84) 22.2 (16.7–28.5) 0.07 (0.06–0.09)
POST 99.1 (94.9–100) 7.77a (6.31–9.57) 100 (96.5–100) 12.32a (10.23–14.83) 81.7 (75.6–86.8) 0.69 (0.58–0.83)
Serotype 14 PRE 84.4 (76.2–90.6) 0.94 (0.68–1.29) 93.3 (86.6–97.3) 1.57 (1.17–2.09) 40.4 (33.6–47.5) 0.28 (0.22–0.36)
POST  99.1 (95.0–100) 20.05 (16.34–24.62) 100 (96.5–100) 26.68 (21.97–32.39) 79.9 (73.7–85.2) 1.01 (0.80–1.27)
Serotype 18C PRE 70.0 (60.5–78.4) 0.53 (0.40–0.71) 91.4 (84.4–96.0) 0.81 (0.64–1.02) 20.5 (15.2–26.7) 0.09 (0.07–0.11)
POST 99.1 (95.0–100) 26.99 (21.69–33.60) 100 (96.5–100) 39.51 (32.84–47.53) 98.5 (95.8–99.7) 3.25 (2.71–3.90)
Serotype 19F PRE 85.5 (77.5–91.5) 1.75 (1.15–2.66) 92.4 (85.5–96.7) 3.20 (2.13–4.80) 60.6 (53.6–67.3) 0.44 (0.32–0.59)
POST  100 (96.6–100) 34.90 (29.40–41.44) 100 (96.6–100) 45.59 (35.17–59.10) 99.0 (96.5–99.9) 4.31 (3.59–5.17)
Serotype 23F PRE 66.4 (56.7–75.1) 0.86 (0.55–1.34) 77.1 (67.9–84.8) 1.09 (0.73–1.61) 24.6 (18.9–31.1) 0.08 (0.07–0.10)
POST 100 (96.7–100) 8.43 (6.73–10.56) 100 (96.6–100) 10.15 (8.02–12.85) 51.0 (43.9–58.0) 0.25 (0.20–0.32)
Cross-reactive serotypes
6A PRE 49.5 (39.8–59.3) 0.29 (0.20–0.42) 60.0 (50.0–69.4) 0.51 (0.35–0.74) 28.0 (22.0–34.7) 0.11 (0.09–0.13)
POST  97.2 (92.2–99.4) 2.02 (1.61–2.52) 95.3 (89.3–98.5) 2.86 (2.20–3.73) 48.8 (41.7–55.9) 0.20 (0.17–0.25)
19A PRE 60.0 (50.2–69.2) 0.39 (0.28–0.55) 78.1 (69.0–85.6) 0.71 (0.50–1.00) 50.7 (43.7–57.7) 0.22 (0.18–0.28)
POST  96.3 (90.8–99.0) 5.40 (3.98–7.34) 100 (96.6–100) 8.47 (6.17–11.62) 73.4 (66.8–79.3) 0.65 (0.52–0.82)
PRE: before PHiD-CV vaccination in the PP and NPP groups; before administration of the ﬁrst dose of PHiD-CV in the control group. POST: 7–10 days after PHiD-CV vaccination
in  the PP and NPP groups; 7–10 days after the ﬁrst dose of PHiD-CV in the control group. N: number of children with available results. The number of subjects tested by ELISA
varied  slightly between time points for the different serotypes depending on the number of sera available; %: percentage of children with concentration within the speciﬁed
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oange; 95% CI: 95% conﬁdence interval.
a No overlap of 95% CIs between the PP group and the NPP group.
ower in the PP group for the remaining serotypes. However, anti-
ody GMCs measured 7–10 days after vaccination in both of these
roups were signiﬁcantly higher than those measured 7–10 days
fter the ﬁrst PHiD-CV dose in the control group (Table 2). Similarly,
PA GMTs in both PHiD-CV primed groups were higher compared
o the control group, with the exception of OPA GMTs for serotypes
V and 18C (Table 3).
Higher anti-protein D antibody GMCs were measured 7–10
ays after PHiD-CV vaccination in the PP group (2266.6
95% CI: 1857.4–2766.0] EL.U/ml) and the NPP group (3178.8
2749.7–3674.9] EL.U/ml) than 7–10 days after the ﬁrst PHiD-CV
ose in the control group (374.3 [315.1–444.6] EL.U/ml).
.3. Carriage
In the previous booster study, NPC rates of vaccine pneumo-
occal serotypes were lower in PHiD-CV vaccinees than in the
ontrol group [14] which was conﬁrmed following re-analysis in
he present study. This reduction was maintained at visit 1 and was
tatistically signiﬁcant at visit 2 (9.4% and 22.1%, respectively). VE
as statistically signiﬁcant for all time points evaluated (Table 4,
upplementary Fig. 2). Similarly, the trends for reduced carriage
ates of any S. pneumoniae serotype (3.8–10.8% lower in PHiD-CV
accinees) and increased carriage rates of non-vaccine and non-
ross reactive serotypes (1.2–3.8% higher in PHiD-CV vaccinees)
ere also sustained (Table 4, Supplementary Fig. 2). No obvious dif-
erences in carriage rates between the PP and NPP groups could be
bserved for neither the vaccine pneumococcal serotypes and/or
ross-reactive serotypes nor for the non-vaccine and non-cross-
eactive pneumococcal serotypes (Table 4, Supplementary Fig. 2).
Supplementary material related to this article found, in the
nline version, at http://dx.doi.org/10.1016/j.vaccine.2013.01.044.Although the VE for the carriage rates of NTHi was statistically
signiﬁcant at the last time point pertaining to the previous booster
study, no consistent effect of PHiD-CV on NTHi carriage rates was
seen in the previous booster study [14] or in the present study
(Table 4, Supplementary Fig. 2). No consistent or statistically sig-
niﬁcant differences were observed between PHiD-CV and control
groups in S. aureus or M. catarrhalis carriage rates (Table 4).
3.4. Safety
One PHiD-CV dose in the fourth year of life in children previ-
ously primed (3 doses) and boosted with PHiD-CV, as well as a ﬁrst
PHiD-CV dose in unprimed children in the fourth year of life, was
well-tolerated (data not shown). One subject of the control group
was  withdrawn before the second study visit after a ﬁrst episode
of epilepsy. No SAEs were reported during this follow-up study.
4. Discussion
We  observed a decline in antibody GMCs and OPA GMTs  in PHiD-
CV-primed and boosted children at 40–48 months of age which
is consistent with previous observations in children aged 36–46
months [9].  However, a substantial proportion of PHiD-CV primed
children exhibited antibody GMCs and OPA GMTs above or equal
to the thresholds, regardless of previous PP administration. High
percentages of subjects in the control group reaching these thresh-
olds for some vaccine pneumococcal serotypes prior to vaccination
with PHiD-CV probably reﬂect past natural exposure.Induction of immunological memory in children previously
vaccinated with PHiD-CV with or without PP was  demonstrated.
Robust increases in antibody GMCs and OPA GMTs were observed
7–10 days following PHiD-CV vaccination and antibody GMCs and
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Table 3
OPA responses, prior to and 7–10 days after PHiD-CV vaccination (PP and NPP groups) or ﬁrst dose of PHiD-CV (control group) – ATP cohort for immunogenicity.
Timing PP group (N = 102) NPP group (N = 99) Control (N = 191)
% >8 (95% CI) GMT (95% CI) % >8 (95% CI) GMT (95% CI) % >8 (95% CI) GMT (95% CI)
Vaccine serotypes
Serotype 1 PRE 21.6 (14.0–30.8) 7.5 (5.7–9.8) 36.1 (26.6–46.5) 14.1 (9.4–20.9) 9.4 (5.7–14.5) 5.4 (4.7–6.2)
POST 100 (96.2–100) 2677.1 (2146.0–3339.7) 100 (96.3–100) 3593.9 (2922.1–4420.2) 98.9 (96.1–99.9) 632.0 (524.4–761.7)
Serotype 4 PRE 25.0 (16.7–34.9) 11.5 (7.7–17.1) 45.2 (34.8–55.8) 28.9 (17.6–47.5) 16.1 (11.0–22.4) 9.1 (6.8–12.1)
POST 99.0  (94.3–100) 23,340.6 (17599.4–30954.8) 100 (96.3–100) 31,718.5 (24963.8–40300.8) 99.5 (97.1–100) 13,109.9 (11080.6–15510.7)
Serotype  5 PRE 29.4 (20.8–39.3) 7.1 (5.8–8.7) 48.5 (38.2–58.8) 11.3 (8.8–14.5) 0.5 (0.0–3.0) 4.0 (4.0–4.1)
POST 99.0  (94.4–100) 852.5 (695.5–1045.0) 100 (96.3–100) 1220.3 (969.3–1536.2) 88.5 (82.9–92.7) 145.8 (111.7–190.3)
Serotype 6B PRE 64.5 (53.9–74.2) 121.6 (67.0–220.7) 75.6 (65.4–84.0) 222.1 (126.0–391.5) 41.6 (34.2–49.3) 46.7 (29.8–73.3)
POST 97.9 (92.7–99.7) 6386.7 (4585.5–8895.3) 100 (96.2–100) 5237.2 (3882.8–7064.2) 90.2 (85.0–94.1) 1472.2 (1053.2–2057.8)
Serotype 7F PRE 100 (96.2–100) 1160.2 (927.1–1451.8) 100 (96.1–100) 1065.0 (853.6–1328.7) 98.2 (94.8–99.6) 973.4 (798.5–1186.6)
POST 100 (96.2–100) 19,386.3 (15148.8–24809.1) 100 (96.2–100) 20,616.8 (16163.4–26297.2) 100 (98.0–100) 13,647.4 (11801.9–15781.3)
Serotype  9V PRE 95.6 (89.0–98.8) 440.0 (323.3–598.9) 98.8 (93.3–100) 532.8 (414.7–684.4) 84.6 (78.0–89.9) 268.2 (192.2–374.3)
POST  100 (96.2–100) 18,806.1 (14406.6–24549.3) 100 (96.3–100) 17,169.8 (12704.8–23204.0) 100 (98.0–100) 14,668.8 (12476.1–17247.0)
Serotype  14 PRE 84.4 (75.5–91.0) 221.6 (143.6–341.9) 89.8 (81.5–95.2) 328.9 (212.0–510.0) 68.7 (61.0–75.6) 145.3 (97.5–216.6)
POST 100 (96.3–100) 14,642.4 (11235.8–19082.0) 100 (96.3–100) 18,068.7 (14101.7–23151.6) 100 (98.0–100) 4454.3 (3921.1–5059.9)
Serotype 18C PRE 31.6 (22.6–41.8) 14.8 (9.5–23.2) 37.5 (27.4–48.5) 13.6 (9.2–20.2) 7.7 (4.2–12.8) 5.7 (4.7–7.0)
POST 98.9  (94.1–100) 7693.4 (5575.6–10615.6) 100 (96.2–100) 7155.4 (5596.6–9148.4) 98.9 (96.0–99.9) 9092.2 (7381.2–11199.9)
Serotype 19F PRE 64.6 (54.4–74.0) 46.3 (28.5–75.2) 83.9 (74.8–90.7) 141.4 (84.2–237.3) 33.3 (26.6–40.6) 12.9 (9.6–17.2)
POST  100 (96.2–100) 5811.9 (4023.0–8396.1) 100 (96.2–100) 6766.7 (4601.7–9950.2) 95.8 (91.9–98.2) 902.5 (659.2–1235.6)
Serotype 23F PRE 65.3 (54.8–74.7) 270.4 (133.9–546.4) 83.0 (73.8–89.9) 796.1 (447.7–1415.4) 60.2 (52.4–67.7) 220.6 (132.0–368.7)
POST 98.0  (92.9–99.8) 13,847.2 (9499.4–20184.9) 100 (96.3–100) 17,626.8 (13421.5–23149.7) 97.9 (94.7–99.4) 5776.5 (4686.8–7119.5)
Cross-reactive serotypes
6A PRE 63.3 (52.5–73.2) 92.6 (53.7–159.5) 64.8 (53.9–74.7) 98.0 (57.6–166.7) 47.9 (40.1–55.8) 49.0 (32.4–74.0)
POST 98.9 (94.2–100) 3228.7 (2258.8–4615.1) 94.9 (88.5–98.3) 1823.6 (1183.1–2810.9) 88.9 (83.4–93.1) 863.3 (619.3–1203.4)
19A PRE  27.3 (18.8–37.1) 12.1 (8.2–18.0) 42.9 (32.5–53.7) 21.3 (13.2–34.3) 25.1 (19.0–32.1) 10.3 (7.9–13.4)
POST  95.8 (89.6–98.8) 2061.8 (1375.8–3090.1) 95.8 (89.7–98.9) 2148.4 (1373.4–3360.8) 91.4 (86.3–95.1) 880.5 (622.7–1245.0)
PRE: before PHiD-CV vaccination in the PP and NPP groups; before administration of the ﬁrst dose of PHiD-CV in the control group. POST: 7–10 days after PHiD-CV vaccination in the PP and NPP groups; 7–10 days after the ﬁrst
dose  of PHiD-CV in the control group. N: number of children with available results. The number of subjects tested for OPA varied slightly between time points for the different serotypes depending on the number of sera available;
%:  percentage of children with titre within the speciﬁed range; 95% CI: 95% conﬁdence interval.
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Table 4
Presence of S. pneumoniae, non-typeable Haemophilus inﬂuenzae and other bacteria in nasopharyngeal swabs, and vaccine efﬁcacy per visit – ATP cohort for carriage.
Control  PHiD-CVa NPP  PP
Carriage  Carriage  VE  Carriage  VE  Carriage  VE
N  n  %  [95%  CI]  N n % [95%  CI]  %[95%  CI]  N n  % [95%  CI]  %[95%  CI]  N n  % [95%  CI] %[95%  CI]
Any  pneumococcal  serotype
24–27 months  (booster  phase)b 209 56 26.8  [20.9;  33.3]  214 43 20.1 [14.9;  26.1]  25.0  [−13.6;  50.8]  105  19  18.1  [11.3;  26.8]  32.5  [−15.4;  62.1]  109  24  22.0 [14.6;  31.0]  17.8  [−34.8;  51.3]
31–44 months  (visit  1)  210  73  34.8  [28.3;  41.6]  216 67 31.0  [24.9;  37.6]  10.8  [−26.1;  36.9]  106  31  29.2  [20.8;  38.9]  15.9  [−29.7;  46.6]  110  36  32.7  [24.1;  42.3]  5.9  [−42.2;  38.7]
40–48 months  (visit  2)  208  91  43.8  [36.9;  50.8]  212 70  33.0  [26.7;  39.8]  24.5  [−4.2;  45.5]  105  36  34.3  [25.3;  44.2]  21.6  [−16.5;  48.3]  107  34  31.8  [23.1;  41.5]  27.4  [−8.8;  52.5]
Any vaccine  pneumococcal  serotype
24–27  months  (booster  phase)b 209 27  12.9  [8.7;  18.2]  214 13 6.1 [3.3;  10.2]  53.0  [5.7;  77.7]  105  4  3.8  [1.0;  9.5]  70.5  [15.4;  92.5]  109  9  8.3  [3.8;  15.1]  36.1  [−40.0;  73.6]
31–44 months  (visit  1)  210  40  19.0 [14.0;  25.0]  216 21 9.7 [6.1;  14.5]  49.0  [11.3;  71.4]  106  9  8.5  [4.0;  15.5]  55.4  [6.7;  81.0]  110  12  10.9  [5.8;  18.3]  42.7  [−11.4;  72.6]
40–48 months  (visit  2)  208  46  22.1  [16.7;  28.4]  212 20  9.4 [5.9;  14.2]  57.3  [26.4;  76.1]  105  12  11.4  [6.0;  19.1]  48.3  [0.9;  75.1]  107  8  7.5  [3.3;  14.2]  66.2  [27.7;  86.2]
Any cross-reactive  pneumococcal  serotypec
24–27 months  (booster  phase)b 209 12  5.7  [3.0;  9.8]  214 10  4.7 [2.3;  8.4]  18.6  [−105.5;  68.5]  105  3  2.9  [0.6;  8.1]  50.2  [−84.4;  91.0]  109  7  6.4  [2.6;  12.8]  −11.9  [−208.1;  62.7]
31–44 months  (visit  1)  210  9  4.3  [2.0;  8.0]  216 13 6.0 [3.2;  10.1]  −40.4  [−272.2;  44.5]  106  7  6.6  [2.7;  13.1]  −54.1  [−365.0;  51.2]  110  6  5.5  [2.0;  11.5]  −27.3  [−300.4;  62.7]
40–48 months  (visit  2)  208  19  9.1  [5.6;  13.9]  212 18 8.5 [5.1;  13.1]  7.1  [−87.1;  54.0]  105  10  9.5  [4.7;  16.8]  −4.3  [−135.7;  56.7]  107  8  7.5  [3.3;  14.2]  18.2  [−95.8;  69.0]
Non-vaccine and  non-cross-reactive  serotypes
24–27 months  (booster  phase)b 209 17  8.1  [4.8;  12.7]  214 20  9.3 [5.8;  14.1]  −14.9 [−133.5;  42.8]  105  12  11.4  [6.0;  19.1]  −40.5  [−212.2;  38.8]  109  8  7.3  [3.2;  14.0]  9.8  [−120.6;  66.3]
31–44 months  (visit  1)  210  25  11.9  [7.9;  17.1]  216 34 15.7 [11.2;  21.3]  −32.2 [−131.2;  23.4]  106  16  15.1  [8.9;  23.4]  −26.8  [−147.0;  36.7]  110  18  16.4  [10.0;  24.6]  −37.5  [−162.3;  29.3]
40–48 months  (visit  2)  208  27  13.0 [8.7;  18.3]  212 35 16.5 [11.8;  22.2]  −27.2 [−118.5;  25.2]  105  15  14.3  [8.2;  22.5]  −10.1  [−114.4;  45.6]  107  20  18.7  [11.8;  27.4]  −44.0  [−166.5;  23.4]
Non-typeable Haemophilus  inﬂuenzae
24–27  months  (booster  phase)b 208 36  17.3  [12.4;  23.1]  213 18 8.5 [5.1;  13.0]  51.2  [11.7;  73.9]  104  15  14.4  [8.3;  22.7]  16.7  [−56.1;  57.6]  109  3  2.8  [0.6;  7.8]  84.1  [49.7;  96.9]
31–44 months  (visit  1)  210  39  18.6  [13.6;  24.5]  216 51 23.6 [18.1;  29.8]  −27.1 [−98.1;  17.8]  106  23  21.7  [14.3;  30.8]  −16.8  [−100.6;  33.4]  110  28  25.5  [17.6;  34.6]  −37.1  [−128.5;  18.8]
40–48 months  (visit  2)  208  81  38.9  [32.3;  45.9]  212 71 33.5 [27.2;  40.3]  14.0  [−19.8;  38.4]  105  39  37.1  [27.9;  47.1]  4.6  [−41.4;  36.6]  107  32  29.9  [21.4;  39.5]  23.2  [−17.0;  50.7]
Staphylococcus aureus
24–27 months  (booster  phase)b 209 46  22.0 [16.6;  28.2]  214 67 31.3 [25.2;  38.0]  −42.2 [−111.8;  3.7]  105  39  37.1  [27.9;  47.1]  −68.8  [−164.3;  −7.3]  109  28  25.7  [17.8;  34.9]  −16.7  [−90.7;  29.7]
31–44 months  (visit  1)  210  47  22.4  [16.9;  28.6]  216 46 21.3 [16.0;  27.4]  4.8  [−46.0;  38.0]  106  25  23.6  [15.9;  32.8]  −5.4  [−74.7;  37.8]  110  21  19.1  [12.2;  27.7]  14.7  [−45.5;  51.6]
40–48 months  (visit  2)  208  26  12.5  [8.3;  17.8]  212 40  18.9 [13.8;  24.8]  −50.9  [−157.6;  10.1]  105  21  20.0  [12.8;  28.9]  −60.0  [−195.7;  14.4]  107  19  17.8  [11.0;  26.3]  −42.1  [−166.8;  25.7]
Moraxella catarrhalis
24–27  months  (booster  phase)b 209 59  28.2  [22.2;  34.9]  214 51 23.8 [18.3;  30.1]  15.6  [−24.9;  43.1]  105  29  27.6  [19.3;  37.2]  2.2  [−55.1;  39.5]  109  22  20.2  [13.1;  28.9]  28.5  [−18.4;  58.3]
31–44 months  (visit  1)  210  74  35.2  [28.8;  42.1]  216 96 44.4 [37.7;  51.3]  −26.1 [−73.2;  7.8]  106  56  52.8  [42.9;  62.6]  −49.9  [−115.0;  −4.0]  110  40  36.4  [27.4;  46.1]  −3.2  [−53.6;  31.6]
40–48 months  (visit  2)  208  99  47.6  [40.6;  54.6]  212 93 43.9 [37.1;  50.8]  7.8  [−23.6;  31.3]  105  44  41.9  [32.3;  51.9]  12.0 [−26.8;  39.7]  107  49  45.8  [36.1;  55.7]  3.8  [−36.8;  33.1]
N: number of swabs cultured at the considered visit; n/%: number/percentage of swabs associated to the speciﬁed bacteria at the considered visit; VE: vaccine efﬁcacy for the indicated group versus the control group was estimated
as  [(1 − relative risk × 100] and was calculated with 95% CI (conditional exact method).
a PHiD-CV: pooled PP and NPP groups.
b Carriage results related to time points of the previous booster study were re-analysed and presented here based on the ATP cohort for carriage of the current study.
c Any serotype belonging to the same serogroup as the PHiD-CV vaccine serotypes, but different from the vaccine serotypes.
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PA GMTs were markedly higher in primed groups than those
easured after a ﬁrst PHiD-CV-dose in the control group for most
erotypes. This observation is in line with previous ﬁndings [9].
nduction of immunological memory is a key characteristic of the
mmune response induced by polysaccharide–protein conjugate
accines. It is based on activation and proliferation of memory
ells to form IgG-secreting plasma cells in primed subjects and it
s believed to be a cornerstone for long-term protection against
isease [22,23].
In line with other studies [24,25], a long-term reduction in NPC
f vaccine pneumococcal serotypes and sustained trends in reduced
PC of any S. pneumoniae serotype despite a trend for increased NPC
f non-vaccine and non-cross reactive serotypes were observed in
HiD-CV vaccinees. Since NPC of S. pneumoniae is known to be cru-
ial in the spread of pneumococcal infection, long-term reduction
n carriage rates might play a role in the establishment of herd
mmunity against pneumococcal disease.
As observed following primary and booster vaccination [15],
rends towards lower antibody GMCs and OPA GMTs were observed
n children previously vaccinated with concomitant use of PP
ompared to children previously vaccinated without prophylactic
ntipyretics. Although these differences persisted also following
HiD-CV vaccination in this study, antibody GMCs for all vaccine
neumococcal serotypes and OPA GMTs for most vaccine pneu-
ococcal serotypes were substantially higher in the PP and NPP
roups compared to the control group. Overall, similar increases in
ntibody GMCs and OPA GMTs between pre- and post-vaccination
ime points were observed in the PP group compared to the NPP
roup conﬁrming the previous observation that PP seems to mainly
ffect immune responses following primary vaccination [15]. Based
n these ﬁndings, it can be concluded that immunological memory
as induced regardless of previous use of PP implying that the clin-
cal relevance of the differences between PP and NPP groups may
ikely be limited.
The observation that initial differences in carriage rates between
P and NPP groups in terms of vaccine pneumococcal serotypes and
on-vaccine non-cross-reactive serotypes seemed to wane over
ime following booster vaccination is conﬁrmed in this study, espe-
ially at the later time points.
A potential limitation of the present study is the possible
cquisition of natural immunity to pneumococcal serotypes in
he age-matched control group before ﬁrst PHiD-CV vaccination.
owever, given the overall differences in antibody GMCs and
PA GMTs between primed and unprimed groups before PHiD-
V re-vaccination, it seems unlikely that natural immunity would
ave impacted the conclusions on immunological memory follow-
ng PHiD-CV priming. On the contrary, natural exposure inducing
mmune responses would actually rather have reduced differences
etween primed and unprimed groups. Another limitation is the
elatively small sample size hampering ﬁrm conclusions on long-
erm effects of PP or detection of minor differences in carriage rates
etween groups. Given the consistency with previous studies, it
ppears unlikely that the use of a non-randomised control group
nd drop-out rates from the booster study would have inﬂuenced
he study outcome. Finally, indirect effects from vaccinated chil-
ren living in the vicinity of children enrolled in the study cannot
e excluded, but is considered to be limited since there was no uni-
ersal vaccination with PCVs in the Czech Republic at the time of
tudy conduct, and not more than 20% of infants were estimated to
ave received PCVs.. Conclusions
Regardless of whether previous PHiD-CV vaccination was given
ith or without PP, induction of immunological memory and1 (2013) 2080– 2088 2087
persistence of carriage impact was shown until at least 28 months
post-booster vaccination. Our study results therefore suggest that
the lower immune responses after primary and booster vaccination
with PP are of transient nature.
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